Literature DB >> 15728879

Evaluation of ceftobiprole in a rabbit model of aortic valve endocarditis due to methicillin-resistant and vancomycin-intermediate Staphylococcus aureus.

Henry F Chambers1.   

Abstract

Ceftobiprole is a novel broad-spectrum cephalosporin that binds with high affinity to PBP 2a, the methicillin-resistance determinant of staphylococci, and is active against methicillin- and vancomycin-resistant Staphylococcus aureus. Ceftobiprole was compared to vancomycin in a rabbit model of methicillin-resistant S. aureus aortic valve endocarditis. Ceftobiprole and vancomycin were equally effective against endocarditis caused by methicillin-resistant S. aureus strain 76, whereas ceftobiprole was more effective than vancomycin against the vancomycin-intermediate S. aureus strain HIP5836. The activity of ceftobiprole against drug-resistant strains of S. aureus warrants its further clinical development.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15728879      PMCID： PMC549268          DOI： 10.1128/AAC.49.3.884-888.2005

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  19 in total

1.  Reversion of the glycopeptide resistance phenotype in Staphylococcus aureus clinical isolates.

Authors:  S Boyle-Vavra; S K Berke; J C Lee; R S Daum
Journal:  Antimicrob Agents Chemother       Date:  2000-02       Impact factor: 5.191

2.  Single-dose pharmacokinetics and safety of a novel broad-spectrum cephalosporin (BAL5788) in healthy volunteers.

Authors:  Anne Schmitt-Hoffmann; Brigitte Roos; Michael Schleimer; Jill Sauer; Anthony Man; Norman Nashed; Thomas Brown; Antonio Perez; Erhard Weidekamm; Péter Kovács
Journal:  Antimicrob Agents Chemother       Date:  2004-07       Impact factor: 5.191

3.  BAL9141, a novel extended-spectrum cephalosporin active against methicillin-resistant Staphylococcus aureus in treatment of experimental endocarditis.

Authors:  J M Entenza; P Hohl; I Heinze-Krauss; M P Glauser; P Moreillon
Journal:  Antimicrob Agents Chemother       Date:  2002-01       Impact factor: 5.191

4.  Structural basis for the beta lactam resistance of PBP2a from methicillin-resistant Staphylococcus aureus.

Authors:  Daniel Lim; Natalie C J Strynadka
Journal:  Nat Struct Biol       Date:  2002-11

5.  In vitro and in vivo properties of Ro 63-9141, a novel broad-spectrum cephalosporin with activity against methicillin-resistant staphylococci.

Authors:  P Hebeisen; I Heinze-Krauss; P Angehrn; P Hohl; M G Page; R L Then
Journal:  Antimicrob Agents Chemother       Date:  2001-03       Impact factor: 5.191

6.  In vitro and in vivo activities of a novel cephalosporin, BMS-247243, against methicillin-resistant and -susceptible staphylococci.

Authors:  Joan C Fung-Tomc; Junius Clark; Beatrice Minassian; Michael Pucci; Yuan-Hwang Tsai; Elizabeth Gradelski; Lucinda Lamb; Ivette Medina; Elizabeth Huczko; Benjamin Kolek; Susan Chaniewski; Cheryl Ferraro; Thomas Washo; Daniel P Bonner
Journal:  Antimicrob Agents Chemother       Date:  2002-04       Impact factor: 5.191

7.  Antibacterial susceptibility of a vancomycin-resistant Staphylococcus aureus strain isolated at the Hershey Medical Center.

Authors:  Bulent Bozdogan; Duygu Esel; Cynthia Whitener; Frederick A Browne; Peter C Appelbaum
Journal:  J Antimicrob Chemother       Date:  2003-10-16       Impact factor: 5.790

8.  PBP 2a mutations producing very-high-level resistance to beta-lactams.

Authors:  Yuki Katayama; Hong-Zhong Zhang; Henry F Chambers
Journal:  Antimicrob Agents Chemother       Date:  2004-02       Impact factor: 5.191

9.  Multiple-dose pharmacokinetics and safety of a novel broad-spectrum cephalosporin (BAL5788) in healthy volunteers.

Authors:  Anne Schmitt-Hoffmann; Lars Nyman; Brigitte Roos; Michael Schleimer; Jill Sauer; Norman Nashed; Thomas Brown; Anthony Man; Erhard Weidekamm
Journal:  Antimicrob Agents Chemother       Date:  2004-07       Impact factor: 5.191

10.  Efficacy of BAL5788, a prodrug of cephalosporin BAL9141, in a mouse model of acute pneumococcal pneumonia.

Authors:  E Azoulay-Dupuis; J P Bédos; J Mohler; A Schmitt-Hoffmann; M Schleimer; S Shapiro
Journal:  Antimicrob Agents Chemother       Date:  2004-04       Impact factor: 5.191
View more
  23 in total

1.  Evaluation of ceftobiprole activity against a variety of gram-negative pathogens, including Escherichia coli, Haemophilus influenzae (β-lactamase positive and β-lactamase negative), and Klebsiella pneumoniae, in a rabbit meningitis model.

Authors:  A Stucki; M Cottagnoud; F Acosta; U Egerman; J Läuffer; P Cottagnoud
Journal:  Antimicrob Agents Chemother       Date:  2011-11-07       Impact factor: 5.191

2.  Comparative in vitro activity of ceftobiprole against staphylococci displaying normal and small-colony variant phenotypes.

Authors:  Christof von Eiff; Alexander W Friedrich; Karsten Becker; Georg Peters
Journal:  Antimicrob Agents Chemother       Date:  2005-10       Impact factor: 5.191

3.  Intensive therapy with ceftobiprole medocaril of experimental foreign-body infection by methicillin-resistant Staphylococcus aureus.

Authors:  Pierre Vaudaux; Asllan Gjinovci; Manuela Bento; Dongmei Li; Jacques Schrenzel; Daniel P Lew
Journal:  Antimicrob Agents Chemother       Date:  2005-09       Impact factor: 5.191

Review 4.  Antimicrobial agents for treatment of serious infections caused by resistant Staphylococcus aureus and enterococci.

Authors:  G M Eliopoulos
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-12       Impact factor: 3.267

5.  In vivo synergism of ceftobiprole and vancomycin against experimental endocarditis due to vancomycin-intermediate Staphylococcus aureus.

Authors:  J M Entenza; T R Veloso; J Vouillamoz; M Giddey; P Majcherczyk; P Moreillon
Journal:  Antimicrob Agents Chemother       Date:  2011-07-05       Impact factor: 5.191

6.  Antistaphylococcal activity of ceftobiprole, a new broad-spectrum cephalosporin.

Authors:  Tatiana Bogdanovich; Lois M Ednie; Stuart Shapiro; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2005-10       Impact factor: 5.191

7.  Efficacy of Telavancin in a rabbit model of aortic valve endocarditis due to methicillin-resistant Staphylococcus aureus or vancomycin-intermediate Staphylococcus aureus.

Authors:  Andres G Madrigal; Li Basuino; Henry F Chambers
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

8.  Results of a double-blind, randomized trial of ceftobiprole treatment of complicated skin and skin structure infections caused by gram-positive bacteria.

Authors:  Gary J Noel; Richard S Strauss; Karen Amsler; Markus Heep; Rienk Pypstra; Joseph S Solomkin
Journal:  Antimicrob Agents Chemother       Date:  2007-10-22       Impact factor: 5.191

9.  In vivo activity of ceftobiprole in murine skin infections due to Staphylococcus aureus and Pseudomonas aeruginosa.

Authors:  Jeffrey Fernandez; Jamese J Hilliard; Darren Abbanat; Wenyan Zhang; John L Melton; Colleen M Santoro; Robert K Flamm; Karen Bush
Journal:  Antimicrob Agents Chemother       Date:  2009-11-02       Impact factor: 5.191

10.  In vivo efficacy of ceftaroline (PPI-0903), a new broad-spectrum cephalosporin, compared with linezolid and vancomycin against methicillin-resistant and vancomycin-intermediate Staphylococcus aureus in a rabbit endocarditis model.

Authors:  Cédric Jacqueline; Jocelyne Caillon; Virginie Le Mabecque; Anne-Françoise Miègeville; Antoine Hamel; Denis Bugnon; James Yigong Ge; Gilles Potel
Journal:  Antimicrob Agents Chemother       Date:  2007-06-25       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.